Berlex ABOVE Study Will Evaluate Switching Avonex MS Patients To Betaseron
This article was originally published in Pharmaceutical Approvals Monthly
Berlex/Chiron’s ABOVE (Interferon beta-1a vs. Interferon beta-1b Observation of Efficacy) study will evaluate whether there is a benefit to switching relapsing-remitting MS patients from once-weekly treatment with Biogen’s Avonex to Berlex’ more frequently administered and higher-dose Betaseron.
You may also be interested in...
Berlex/Chiron’s Betaseron indication has been expanded to include secondary progressive multiple sclerosis, but approval is limited to the subset of patients who continue to have relapsing disease.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011